8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

April 19, 2005

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
11588 Sorrento Valley Road, Suite 17, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 8.01 Other Events.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Item 8.01 Other Events.

On April 19, 2005, Halozyme Therapeutics, Inc. (the “Company”) announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CumulaseÔ for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The press release announcing the Company’s 510(k) clearance is filed as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

     (c) Exhibits.

Exhibit No.	Description
99.1	Press Release dated April 19, 2005.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
April 19, 2005	By:	/s/ Jonathan E. Lim, MD
		Jonathan E. Lim, MD
		President and CEO

EX-99.1

                                                                    Exhibit 99.1


                          (HALOZYME THERAPEUTICS LOGO)


HALOZYME CONTACT                             INVESTOR RELATIONS CONTACTS
David A. Ramsay                              Ina McGuinness / Bruce Voss
Chief Financial Officer                      Lippert/Heilshorn & Associates
(858) 794-8889                               (310) 691-7100
dramsay@halozyme.com                         imcguinness@lhai.com

                                             MEDIA CONTACTS
                                             Kathy Sweeney / Joleen Schultz
                                             Mentus
                                             (858) 455-5500, x230/x215
                                             kwitz@mentus.com
                                             jschultz@mentus.com


                    HALOZYME THERAPEUTICS RECEIVES FDA 510(K)
                             CLEARANCE FOR CUMULASE

SAN DIEGO, APRIL 19, 2005 - Halozyme Therapeutics, Inc. (AMEX: HTI), a
development stage biopharmaceutical company focused on the development and
commercialization of recombinant human enzymes, today announced it has received
510(k) clearance from the U.S. Food and Drug Administration (FDA) for
Cumulase(TM) for the treatment of oocytes to facilitate certain in vitro
fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase
is the first and only recombinant human hyaluronidase approved in the United
States for cumulus removal in the IVF process.

"We are thrilled to receive FDA 510(k) clearance to market our first product in
the U.S.," said Jonathan Lim, MD, Halozyme's Chairman and CEO. "This achievement
is a key milestone for our company and provides validation of our technology and
our team's ability to develop and commercialize products based on recombinant
human hyaluronidase."

Cumulase is an ex vivo formulation of rHuPH20 (recombinant human PH20
hyaluronidase) to replace bovine and ovine extracts currently used for the
preparation of oocytes prior to IVF during the process of intracytoplasmic sperm
injection (ICSI), in which the enzyme is an essential component. The enzyme
strips away the hyaluronic acid that surrounds the oocyte, allowing the
clinician to then perform ICSI, injecting the sperm into the oocyte. Cumulase
provides the IVF specialist with a safer, purer and more reliable alternative to
slaughterhouse-derived extracts.

The total Cumulase market consists of an estimated 500,000 ICSI cycles worldwide
in 2005, with nearly 90,000 of those performed in the U.S. Halozyme received CE
Mark approval of

Cumulase in late 2004 to market the product throughout the EU. The company has
signed agreements with Cook Ob/Gyn Incorporated, MediCult A/S, and MidAtlantic
Diagnostics, Inc., to distribute Cumulase worldwide. In February, Halozyme
signed a commercial manufacturing supply agreement with Avid Bioservices to
manufacture the recombinant human enzyme under current good manufacturing
practices (cGMPs).

ABOUT HALOZYME THERAPEUTICS, INC.

Halozyme is a development stage biopharmaceutical company dedicated to
developing and commercializing recombinant human enzymes for the infertility,
ophthalmology, and oncology communities. The company's portfolio of products
under development is based on intellectual property covering the family of human
enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may
replace current animal slaughterhouse-derived enzymes that carry potential risks
of animal pathogen transmission and immunogenicity. The versatility of the first
enzyme, rHuPH20, enables Halozyme to develop the product as a medical device,
drug enhancement agent, and therapeutic biologic.

SAFE HARBOR STATEMENT

In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements concerning
the Company's products and the market sizes for these products) that involve
risk and uncertainties that could cause actual results to differ materially from
those in the forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may," "will," "could,"
"intends," "estimate," "anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar meaning. Actual
results could differ materially from the expectations contained in
forward-looking statements as a result of several factors, including regulatory
approval requirements and competitive conditions. These and other factors that
may result in differences are discussed in greater detail in the company's
reports on Forms 10-KSB, 10-QSB and other filings with the Securities and
Exchange Commission.

                                      ###